Last reviewed · How we verify
Antiplatelets
At a glance
| Generic name | Antiplatelets |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes
- Identifying Risk Factors and Predicting Future Health Outcomes for Korean Patients With Heart and Blood Vessel Diseases: A Long-term Follow-up Study
- Phone-based Intervention Under Nurse Guidance After Stroke 2 (PHASE3)
- Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD) (NA)
- Healthcare Services for Older People Who Have Fallen With Potential Head Injury
- StrokeNet Thrombectomy Endovascular Platform (NA)
- SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiplatelets CI brief — competitive landscape report
- Antiplatelets updates RSS · CI watch RSS
- Pfizer portfolio CI